Effects of isoliquiritigenin on the expression of MMP-9 and TIMP-1 protease after brain injury in rats

doi:10.3877/cma.j.issn.2095-9141.2021.04.002

Abstract

Abstract:

Objective

To observe the effect of isoliquiritigenin (ISL) on the expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in brain tissue of rats with traumatic brain injury (TBI).

Methods

Thirty clean grade Wistar rats, weighing 200-250 g, were randomly divided into normal control group (n=10), TBI model group (n=10) and ISL group (n=10). The normal control group was given normal feeding; TBI model group and ISL group were established by modified Feeney method, and closed TBI was induced by free fall impact; The ISL group was given ISL intervention 2-4 h after successful modeling, and the dosage was 30 mg/(kg·d) by gavage for 2 weeks. The expressions of MMP-9 and TIMP-1 were detected by ELISA.

Results

The expression of MMP-9 was strong in normal control group and decreased in TBI model group, and the expression of MMP-9 in ISL group was weaker than in the TBI model group (P<0.05). The expression of TIMP-1 in the normal control group was evident and decreased in TBI model group, and the expression of TIMP-1 in ISL group was significantly higher than that in the TBI model group (P<0.05).

Conclusion

ISL can reduce the permeability of microvascular basement and reduce the degree of brain edema in rats with TBI, and its mechanism may be related to increasing the expression of TIMP-1 to regulate the balance of MMP-9.

Key words: Craniocerebral injury, Isoliquiritigenin, Matrix metalloproteinase-9, Tissue inhibitor of metalloproteinase-1

Changdong Li, Jie Zhou, Zhibiao Cai, Kai Wang. Effects of isoliquiritigenin on the expression of MMP-9 and TIMP-1 protease after brain injury in rats[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2021, 07(04): 199-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2021.04.002

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2021/V07/I04/199

Figures/Tables 2

References 17

[1]	Liu J, Xiong X, Sui Y. Isoliquiritigenin attenuates neuroinflammation in traumatic brain injury in young rats[J]. Neuroimmunomodulation, 2019, 26(2): 102-110.
[2]	Lee DG, Min JS, Lee HS, et al. Isoliquiritigenin attenuates glutamate-induced mitochondrial fission via calcineurin-mediated Drp1 dephosphorylation in HT22 hippocampal neuron cells[J]. Neurotoxicology, 2018, 68: 133-141.
[3]	Shi D, Yang J, Jiang Y, et al. The antioxidant activity and neuroprotective mechanism of isoliquiritigenin[J]. Free Radic Biol Med, 2020, 152: 207-215.
[4]	Alzahrani S, Ajwah SM, Alsharif SY, et al. Isoliquiritigenin downregulates miR-195 and attenuates oxidative stress and inflammation in STZ-induced retinal injury[J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(12): 2375-2385.
[5]	Alzahrani S, Zaitone SA, Said E, et al. Protective effect of isoliquiritigenin on experimental diabetic nephropathy in rats: Impact on Sirt-1/NFκB balance and NLRP3 expression[J]. Int Immunopharmacol, 2020, 87: 106813.
[6]	Alshangiti AM, Togher KL, Hegarty SV, et al. The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells[J]. Neuronal Signal, 2019, 3(1): NS20180201.
[7]	Cao LJ, Yan M, Ma YX, et al. Isoliquiritigenin protects against triptolide-induced hepatotoxicity in mice through Nrf2 activation[J]. Pharmazie, 2016, 71(7): 394-397.
[8]	Cao M, Zhan M, Wang Z, et al. Development of an orally bioavailable isoliquiritigenin self-nanoemulsifying drug delivery system to effectively treat ovalbumin-induced asthma[J]. Int J Nanomedicine, 2020, 15: 8945-8961.
[9]	Chen C, Huang S, Chen CL, et al. Isoliquiritigenin inhibits ovarian cancer metastasis by reversing epithelial-to-mesenchymal transition[J]. Molecules, 2019, 24(20): 3725.
[10]	Chen C, Shenoy AK, Padia R, et al. Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2’, 4’-Tetrahydroxychalcone[J]. J Exp Clin Cancer Res, 2018, 37(1): 243.
[11]	郝文龙，荔志云. 异甘草素在脑胶质瘤治疗中的作用与进展[J]. 西北国防医学杂志, 2019, 40(4): 255-259.
[12]	Chi JH, Seo GS, Cheon JH, et al. Isoliquiritigenin inhibits TNF-α-induced release of high-mobility group box 1 through activation of HDAC in human intestinal epithelial HT-29 cells[J]. Eur J Pharmacol, 2017, 796: 101-109.
[13]	孙建军，周杰，李长栋, 等. 异甘草素对颅脑损伤大鼠IL-6和IL-10表达的影响[J]. 中华神经创伤外科电子杂志, 2021, 7(1): 12-16.
[14]	Gao Y, Lv X, Yang H, et al. Isoliquiritigenin exerts antioxidative and anti-inflammatory effects via activating the KEAP-1/Nrf2 pathway and inhibiting the NF-κB and NLRP3 pathways in carrageenan-induced pleurisy[J]. Food Funct, 2020, 11(3): 2522-2534.
[15]	Qi J, Cui J, Mi B, et al. Isoliquiritigenin inhibits atherosclerosis by blocking TRPC5 channel expression[J]. Cardiovasc Ther, 2020, 2020: 1926249.
[16]	李长栋，荔志云，白海, 等. 大黄素甲醚联合脐带间充质干细胞移植对创伤性脑损伤大鼠MMP-9和TIMP-1蛋白酶的影响[J]. 创伤外科杂志, 2013, 15(4): 306-309.
[17]	Ralay Ranaivo H, Hodge JN, Choi N, et al. Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways[J]. J Neuroinflammation, 2012, 9: 68.

组别	只数	MMP-9阳性表达	TIMP-1阳性表达
正常对照组	10	35.81±0.03	64.85±0.03
TBI模型组	10	33.81±0.02^a	21.53±0.03^a
ISL组	10	21.53±0.03^ab	42.78±0.05^ab
F值		7.310	7.050
P值		0.011	0.031

组别	只数	MMP-9阳性表达	TIMP-1阳性表达
正常对照组	10	35.81±0.03	64.85±0.03
TBI模型组	10	33.81±0.02^a	21.53±0.03^a
ISL组	10	21.53±0.03^ab	42.78±0.05^ab
F值		7.310	7.050
P值		0.011	0.031

Please choose a citation manager

Content to export